



4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis

Daniela Secci, Simone Carradori, Anél Petzer, Paolo Guglielmi, Melissa D'Ascenzio, Paola Chimenti, Donatella Bagetta, Stefano Alcaro, Gokhan Zengin, Jacobus P. Petzer & Francesco Ortuso

To cite this article: Daniela Secci, Simone Carradori, Anél Petzer, Paolo Guglielmi, Melissa D'Ascenzio, Paola Chimenti, Donatella Bagetta, Stefano Alcaro, Gokhan Zengin, Jacobus P. Petzer & Francesco Ortuso (2019) 4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 34:1, 597-612, DOI: [10.1080/14756366.2019.1571272](https://doi.org/10.1080/14756366.2019.1571272)

To link to this article: <https://doi.org/10.1080/14756366.2019.1571272>



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 06 Feb 2019.



Submit your article to this journal [↗](#)



Article views: 134



View Crossmark data [↗](#)

RESEARCH PAPER



4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis

Daniela Secci^a, Simone Carradori^b , Anél Petzer^c, Paolo Guglielmi^a, Melissa D'Ascenzio^{a*}, Paola Chimenti^a, Donatella Bagetta^d, Stefano Alcaro^d, Gokhan Zengin^e , Jacobus P. Petzer^c and Francesco Ortuso^d

^aDipartimento di Chimica e Tecnologie del Farmaco, Sapienza University of Rome, Rome, Italy; ^bDepartment of Pharmacy, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy; ^cPharmaceutical Chemistry, School of Pharmacy, and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa; ^dDipartimento di Scienze della Salute, "Magna Graecia" University of Catanzaro, Catanzaro, Italy; ^eDepartment of Biology, Science Faculty, Selcuk University, Konya, Turkey

ABSTRACT

A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives were designed, synthesised, and evaluated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms. Different (un)substituted (hetero)aromatic substituents were linked to N1 of the hydrazone in order to establish robust structure–activity relationships. The results of the biological testing demonstrated that the presence of the hydrazothiazole nucleus bearing at C4 a phenyl ring functionalised at the *meta* position with a nitro group represents an important pharmacophoric feature to obtain selective and reversible human MAO-B inhibition for the treatment of neurodegenerative disorders. In addition, the most potent and selective MAO-B inhibitors were evaluated *in silico* as potential cholinesterase (AChE/BuChE) inhibitors and *in vitro* for antioxidant activities. The results obtained from molecular modelling studies provided insight into the multiple interactions and structural requirements for the reported MAO inhibitors properties.

ARTICLE HISTORY

Received 22 November 2018
Revised 26 December 2018
Accepted 28 December 2018

KEYWORDS

(Thiazol-2-yl)hydrazone derivatives; Alzheimer's disease; Parkinson's disease; selective; monoamine oxidase; inhibitor; antioxidants; molecular modelling

1. Introduction

Neurodegenerative disorders (NDDs) are primarily characterised by an extensive loss of neurons in specific areas of the brain underlying a progressive decline in motor and cognitive functions. The patients suffering from NDDs share a large plethora of pathogenic mechanisms and symptomatology¹. To overcome such multifactorial diseases, an effective approach should consider molecules able to modulate different pathways. These scaffolds must be chosen among those recognised to interact pleiotropically with important and crucial systems such as monoamine oxidase (MAO-A and MAO-B), cholinesterases [acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE)], and ROS producers. The same molecule, endowed with a multi-target activity and characterised chemically and physically, could represent an innovative advance for the treatment of complex NDDs². Among NDDs, Parkinson's disease (PD) is of much interest to researchers involved in the design and synthesis of multi-target-direct ligands in the last few years^{3,4}. Among the several proposed scaffolds, we recently explored thiazolylhydrazones as dual-target-directed agents which acts at both MAO-B and AChE, while also possessing antioxidative effects^{5,6}. These compounds displayed very potent inhibitory activity and selectivity against the human monoamine oxidase (hMAO)-B isoform and discrete AChE inhibition and ROS scavenging effects.

Human MAOs are of great medicinal importance due to their unique role in modulating the function/activity of specific

neurotransmitters (i.e. dopamine) in various pathogenic central nervous system (CNS) conditions (PD, mood disorders, anxiety and depression, migraine, aggressive behaviour)^{7–13}. Particularly, the expression of the MAO-B isoform in human brain increases with age and has been linked to neurodegeneration, a process which may be attributed to glial cell proliferation (where it is mainly localised) as a result of neuronal loss in specific CNS regions. An excessive dopamine turnover catalyzed by MAO-B with consequent hydrogen peroxide-mediated production of ROS and reactive final products (aldehydes and ammonia) further links MAO-B to neurodegeneration¹⁴.

Selective MAO-B inhibitors could thus restore the dopamine concentration in the basal ganglia and limit ROS-induced neurotoxicity as well-recognised for the clinically used drugs in this class (selegiline, rasagiline, safinamide)^{15,16}.


Previous studies have also shown the correlation between MAO-B and Alzheimer's disease (AD) due to (i) the increase of MAO-B activity in brain and platelets in AD patients, (ii) the MAO-B specific ligand 11C-deuterium-L-deprenyl showed enhanced binding in presymptomatic familial AD patients, and (iii) AD patients are characterised by enhanced astrocytosis. Moreover, MAO-B was reported to be associated with γ -secretase in the regulation of intraneuronal A β levels especially in pyramidal neurons as well as glia cells in the frontal cortex and hippocampus¹⁷. However, the main pathogenic feature linked with the progression of AD is the weakening of the cholinergic system in the brain and

CONTACT Simone Carradori  simone.carradori@unich.it  Department of Pharmacy, "G. D'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, Chieti 66100, Italy

*Current address: D'Arcy Thompson Unit, School of Life Sciences, University of Dundee, Dundee, DD1 4HN, UK.

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Scheme 1. General structure showing the chemical modification made and synthesis of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives **1–36** and 4-(3-aminophenyl)thiazol-2-ylhydrazone derivative **37**.

inhibitors of AChE and BuChE are approved as a therapeutic strategy to limit the symptoms and progression of AD. The role of BuChE is not completely known yet.

Recently, we designed and synthesised multi-target inhibitors based on thiazol-2-ylhydrazone scaffold with selective MAO-B inhibitory potency for further structural tuning^{18–25}. Pursuing our efforts in the discovery and development of new thiazolyhydrazones effective against NDDs, we extended our study by evaluating derivatives **1–37**, in order to evaluate their hMAOs inhibition profile, chelating properties, antioxidant activity as well as *in silico* AChE and BuChE inhibition properties. These activities determine the efficacy of these compounds to work as multi-target drugs.

2. Chemistry

4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives (**1–36**) were synthesised in high yields as reported in our previous communications (Scheme 1)²⁶. The appropriate carbonyl compound was reacted with thiosemicarbazide in ethanol at room temperature and in presence of acetic acid as the catalyst (Scheme 1, a). The Hantzsch reaction between the resulting thiosemicarbazone and 2-bromo-3'-nitroacetophenone in the same conditions of solvent and temperature gave the corresponding 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives (Scheme 1, b). For the synthesis of the thiophene-containing 4-(3-amino)thiazol-2-ylhydrazone derivative (**37**), reduction of the nitro group was performed using sodium dithionite previously solubilised in a basic aqueous solution and added dropwise to a stirring suspension of compound **3** in tetrahydrofuran at room temperature (Scheme 1, c). All the synthesised products were washed with petroleum ether and diethyl ether and purified by chromatography using silica gel as stationary

phase and the appropriate mixtures of ethyl acetate and petroleum ether as mobile phase. Characterisation and purity assessment of the synthesised compounds were carried out by melting point determination, spectroscopic methods (IR, ¹H and ¹³C NMR) and elemental analysis.

3. Biological characterisation

Compounds **1–37** were evaluated *in vitro* as potential inhibitors of the two human recombinant isoforms of monoamine oxidase (hMAO-A and hMAO-B). For a selected compound, the reversibility/irreversibility of MAO inhibition and mechanism of inhibition (e.g. competitive) were evaluated. Furthermore, with the aim to explore the multi-target profile of these derivatives, we performed tests to determine chelating properties, antioxidant activity as well as the AChE and BuChE inhibition profile.

4. Experimental protocols

Starting materials and reagents used in the synthetic procedures were obtained from commercial suppliers and were used without further purification. Solvents were freshly distilled before use whenever required. All melting points were measured on a Stuart[®] melting point apparatus SMP1, and are uncorrected. IR spectra were measured with a PerkinElmer Spectrum 100 FT-IR spectrophotometer equipped with universal total reflectance (ATR) accessory with absorption frequencies expressed in reciprocal centimetres. ¹H and ¹³C NMR spectra were recorded at 400 MHz on a Bruker spectrometer using CDCl₃ and DMSO-d₆ as the solvents at room temperature. The samples were analyzed at a final concentration of 30 mg/mL. Chemical shifts are

expressed as δ units (parts per millions) relative to the solvent signal. Coupling constants J are valued in Hertz (Hz). The processing and analyses of the NMR data were carried out with MestreNova. Elemental analyses for C, H, and N were recorded on a Perkin-Elmer 240 B microanalyzer obtaining analytical results within $\pm 0.4\%$ of the theoretical values for all compounds. All reactions were monitored by thin layer chromatography (TLC) performed on 0.2 mm thick silica gel-aluminium backed plates (60 F₂₅₄, Merck). Preparative flash column chromatography was carried out on silica gel (230–400 mesh, G60 Merck). All compounds were recrystallised from ethanol. The yields shown are not optimised. Organic solutions were dried over anhydrous sodium sulphate. Evaporation of the solvent after reaction was carried out on a rotary evaporator (Buchi R-210, Milan, Italy).

4.1. General synthetic procedure for the nitro compounds 1–36 and amino compound 37

To a stirring solution of the appropriate carbonyl compound (1.0 eq.) in ethanol (50 ml), thiosemicarbazide (1.0 eq.) and acetic acid as the catalyst were added. The reaction was monitored by TLC up to completion, usually reached in 24–72 h. The obtained suspension was filtered, and the solid washed twice with petroleum ether (20 ml) and diethyl ether (20 ml). The thiosemicarbazone (1.0 eq.), thus synthesised, was reacted with 2-bromo-3'-nitroacetophenone previously dissolved in ethanol (50 ml), and the reaction was magnetically stirred at room temperature until completion as monitored by TLC. The resulting 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivative was collected by filtration, washed with petroleum ether (20 ml) and diethyl ether (20 ml), and purified by column chromatography using ethyl acetate:petroleum ether as mobile phase, to give compounds **1–37** in high yields and purity. With respect to the synthetic approach of compound **36** that is the product of the dimerisation of the parent compound **31**, two equivalents of thiosemicarbazide were used in the first step (Scheme 1, a) and two equivalents of 2-bromo-3'-nitroacetophenone were used in the second step (Scheme 1, b). To obtain the thiophene containing 4-(3-amino)thiazol-2-ylhydrazone derivative (**37**), sodium dithionite (5.5 eq.) was dissolved in a basic solution of water (30 ml) and sodium bicarbonate (5.5 eq.). The resulting solution was added dropwise to a stirring suspension of nitro compound **3** (1.0 eq.) in tetrahydrofuran (50 ml) at room temperature and the reaction was stirred for 2 h (up to completion by TLC). The tetrahydrofuran was evaporated *in vacuo*, the solid that precipitated from the aqueous phase was collected by filtration, washed with water (20 ml) and petroleum ether (20 ml), and dried to give the desired amino derivative **37**. In order to confirm structure and purity of the synthesised test compounds, characterisation was performed using IR, ¹H NMR and ¹³C NMR along with elemental analysis. Melting points were recorded as mp range. The synthesised compounds exist in theory as a mixture of *E* and *Z* isomers. However, the chemical-physical data are characteristic for the most predominant and thermodynamically stable *E* geometric isomer because of the up-shielding observed in the ¹H NMR spectra for the NH signal and for the absence of any *Z*-stabilising functional groups. The *Z* isomer is also undesirable due to steric interaction between the aryl group and the NH moiety²⁷. In general, the IR spectrum (neat) for derivatives **1–37** showed stretching absorption bands at approximately 3310 cm⁻¹ for NH, at 3040 cm⁻¹ due to the stretching of C_{sp2}-H, at 1640 cm⁻¹ for the C=N and at 1585 and 1445 cm⁻¹ for C=C.

4.1.1. 1-(Furan-2-ylmethylene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (1)

Green powder, mp 213–215 °C, 71% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 6.60–6.61 (m, 1H, furan), 6.82–6.83 (m, 1H, furan), 7.64 (s, 1H, C₅H-thiazole), 7.65–7.70 (m, 1H, furan), 7.79–7.81 (m, 1H, Ar), 7.93 (s, 1H, Ar), 8.14–8.16 (m, 1H, Ar), 8.29–8.31 (m, 1H, Ar), 8.65 (s, 1H, =CH), 12.17 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₄H₁₀N₄O₃S: C, 53.50; H, 3.21; N, 17.82. Found: C, 53.26; H, 3.01; N, 17.99.

4.1.2. 1-(1-(Furan-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (2)

Yellow powder, mp 230–234 °C, 68% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.28 (s, 3H, CH₃), 7.38–7.47 (m, 2H, furan), 7.64 (s, 1H, C₅H-thiazole), 7.66–7.75 (m, 1H, furan), 7.87–7.89 (m, 1H, Ar), 8.15–8.18 (m, 1H, Ar), 8.32–8.35 (m, 1H, Ar), 8.74 (s, 1H, Ar), 11.52 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₄H₁₀N₄O₂S₂: C, 54.87; H, 3.68; N, 17.06. Found: C, 55.06; H, 3.51; N, 17.22.

4.1.3. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine (3)

Yellow powder, mp 187–189 °C, 70% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 7.09–7.11 (m, 1H, thiophene), 7.37–7.38 (m, 1H, thiophene), 7.58–7.60 (m, 1H, thiophene), 7.64 (s, 1H, C₅H-thiazole), 7.68–7.72 (t, 1H, Ar), 8.13–8.15 (m, 1H, Ar), 8.23 (s, 1H, Ar), 8.28–8.30 (m, 1H, Ar), 8.66 (s, 1H, =CH), 12.19 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 106.9 (Ar-C5, thiazole), 120.4 (Ar), 122.5 (Ar), 129.8 (Ar, thiophene), 130.7 (Ar), 132.0 (Ar), 134.0 (Ar, thiophene), 136.6 (Ar), 137.5 (Ar, thiophene), 139.5 (Ar, thiophene), 145.9 (C=N), 148.2 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 168.7 (C=N, thiazole). Anal. Calcd for C₁₄H₁₀N₄O₂S₂: C, 50.90; H, 3.05; N, 16.96. Found: C, 51.13; H, 2.88; N, 17.20.

4.1.4. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)ethylidene)hydrazine (4)

Yellow powder, mp 270–272 °C, 74% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.34 (s, 3H, CH₃), 7.05–7.07 (m, 1H, thiophene), 7.35–7.41 (m, 1H, thiophene), 7.44–7.50 (m, 1H, thiophene), 7.65 (s, 1H, C₅H-thiazole), 7.69–7.71 (m, 1H, Ar), 8.11–8.14 (m, 1H, Ar), 8.31–8.35 (m, 1H, Ar), 8.70 (s, 1H, Ar), 11.41 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 15.0 (CH₃), 107.4 (Ar-C5, thiazole), 120.4 (Ar), 122.5 (Ar), 127.1 (Ar, thiophene), 128.1 (Ar, thiophene), 128.4 (Ar, thiophene), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 143.7 (Ar, thiophene), 144.6 (C=N), 148.5 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 168.7 (C=N, thiazole). Anal. Calcd for C₁₅H₁₂N₄O₂S₂: C, 52.31; H, 3.51; N, 16.27. Found: C, 52.05; H, 3.78; N, 16.43.

4.1.5. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(thiophen-3-yl)ethylidene)hydrazine (5)

Yellow powder, mp 183–185 °C, 85% yield; ¹H NMR (400 MHz, CDCl₃): δ 2.39 (s, 3H, CH₃), 7.07 (s, 1H, C₅H-thiazole), 7.36–7.38 (m, 1H, Ar), 7.57 (s, 1H, thiophene), 7.61–7.65 (m, 2H, thiophene), 8.16–8.22 (m, 2H, Ar), 8.66 (s, 1H, Ar), 9.49 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 15.2 (CH₃), 107.2 (Ar-C5, thiazole), 120.4 (Ar), 122.4 (Ar), 124.7 (Ar, thiophene), 125.7 (Ar, thiophene), 127.3 (Ar, thiophene), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 141.7 (Ar, thiophene), 144.6 (C=N), 148.5 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 168.7 (C=N, thiazole). Anal. Calcd for C₁₅H₁₂N₄O₂S₂: C, 52.31; H, 3.51; N, 16.27. Found: C, 52.60; H, 3.27; N, 16.02.

4.1.6. 1-(1-(5-Chlorothiophen-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (6)

Orange powder, mp 227–229 °C, 81% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.29 (s, 3H, CH₃), 7.09 (s, 1H, C₅H-thiazole), 7.26–7.29 (m, 1H, Ar), 7.67–7.73 (m, 2H, thiophene), 8.14–8.32 (m, 2H, Ar), 8.70 (s, 1H, Ar), 11.58 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₅H₁₁ClN₄O₂S₂: C, 47.55; H, 2.93; N, 14.79. Found: C, 47.71; H, 3.17; N, 14.53.

4.1.7. 1-Benzylidene-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (7)

Yellow powder, mp 193–195 °C, 76% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 7.38–7.47 (m, 3H, Ar), 7.67–7.74 (m, 3H, Ar), 8.06 (s, 1H, C₅H-thiazole), 8.15–8.17 (m, 1H, Ar), 8.30–8.32 (m, 1H, Ar), 8.41–8.43 (m, 1H, Ar), 8.69 (s, 1H, =CH), 12.31 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₆H₁₂N₄O₂S: C, 59.25; H, 3.73; N, 17.27. Found: C, 58.99; H, 3.98; N, 17.02.

4.1.8. 1-(2-Nitrobenzylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (8)

Orange powder, mp 228–230 °C, 79% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 7.63–7.65 (m, 1H, Ar), 7.73–7.74 (m, 2H, Ar), 7.79–7.82 (m, 1H, Ar), 8.04–8.05 (m, 1H, Ar), 8.06 (s, 1H, C₅H-thiazole), 8.16–8.18 (m, 1H, Ar), 8.31–8.33 (m, 1H, Ar), 8.45–8.47 (m, 1H, Ar), 8.69 (s, 1H, =CH), 12.68 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 107.6 (Ar-C5, thiazole), 120.4 (Ar), 122.6 (Ar), 125.2 (Ar), 128.0 (Ar), 128.9 (Ar), 130.3 (Ar), 130.7 (Ar), 132.1 (Ar), 134.0 (Ar), 136.5 (Ar), 137.2 (Ar), 137.6 (C=N), 147.9 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 168.6 (C=N, thiazole). Anal. Calcd for C₁₆H₁₁N₅O₄S: C, 52.03; H, 3.00; N, 18.96. Found: C, 52.27; H, 2.82; N, 19.12.

4.1.9. 1-(3-Nitrobenzylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (9)

Yellow powder, mp 222–224 °C, 81% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 7.67–7.73 (m, 2H, Ar), 8.15 (s, 1H, C₅H-thiazole), 8.17–8.31 (m, 6H, Ar), 8.66 (s, 1H, =CH), 11.62 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₆H₁₁N₅O₄S: C, 52.03; H, 3.00; N, 18.96. Found: C, 52.21; H, 3.24; N, 18.74.

4.1.10. 1-(4-Nitrobenzylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (10)

Characterisation data were in agreement with those reported in the literature²⁸.

4.1.11. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-phenylethylidene)hydrazine (11)

Yellow powder, mp 261–263 °C, 86% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.34 (s, 3H, CH₃), 7.38–7.45 (m, 3H, Ar), 7.67 (s, 1H, C₅H-thiazole), 7.69–7.73 (m, 1H, Ar), 7.77–7.80 (m, 2H, Ar), 8.13–8.16 (m, 1H, Ar), 8.31–8.33 (m, 1H, Ar), 8.72–8.73 (m, 1H, Ar), 11.36 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 14.6 (CH₃), 107.3 (Ar-C5, thiazole), 120.5 (Ar), 122.4 (Ar), 126.2 (2 × Ar), 128.9 (2 × Ar), 129.3 (Ar), 130.7 (Ar), 132.0 (Ar), 136.8 (Ar), 138.3 (Ar), 147.4 (C=N), 148.6 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 170.6 (C=N, thiazole). Anal. Calcd for C₁₇H₁₄N₄O₂S: C, 60.34; H, 4.17; N, 16.56. Found: C, 60.12; H, 4.32; N, 16.79.

4.1.12. 2-(4-(3-Nitrophenyl)thiazol-2-yl)-1-(1-phenylpropylidene)hydrazine (12)

Yellow powder, mp 215–217 °C, 85% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 1.08–1.12 (t, 3H, CH₃), 2.86–2.91 (m, 2H, CH₂), 7.38–7.46 (m, 3H, Ar), 7.69 (s, 1H, C₅H-thiazole), 7.70–7.74 (m, 1H, Ar), 7.79–7.81 (m, 2H, Ar), 8.15–8.17 (d, *J* = 8.0 Hz, 1H, Ar), 8.32–8.34 (d, *J* = 8.0 Hz, 1H, Ar), 8.74 (s, 1H, Ar), 11.55 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₈H₁₆N₄O₂S: C, 61.35; H, 4.58; N, 15.90. Found: C, 61.20; H, 4.32; N, 16.13.

4.1.13. 1-(1-(2-Nitrophenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (13)

Orange powder, mp 195–200 °C, 87% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.34 (s, 3H, CH₃), 7.61–7.65 (m, 2H, 1H Ar + 1H C₅H-thiazole), 7.70–7.78 (m, 3H, Ar), 7.91–7.93 (m, 1H, Ar), 8.15–8.17 (m, 1H, Ar), 8.30–8.31 (m, 1H, Ar), 8.71 (s, 1H, Ar), 11.51 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₇H₁₃N₅O₄S: C, 53.26; H, 3.42; N, 18.27. Found: C, 53.11; H, 3.25; N, 18.54.

4.1.14. 1-(1-(3-Nitrophenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (14)

Orange powder, mp 214–216 °C, 85% yield; ¹H NMR (400 MHz, CDCl₃): δ 2.40 (s, 3H, CH₃), 7.14 (s, 1H, C₅H-thiazole), 7.61–7.63 (m, 2H, Ar), 8.15–8.26 (m, 4H, Ar), 8.63 (s, 1H, Ar), 8.70 (s, 1H, Ar), 8.98 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₇H₁₃N₅O₄S: C, 53.26; H, 3.42; N, 18.27. Found: C, 53.55; H, 3.70; N, 18.09.

4.1.15. 1-(1-(4-Nitrophenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (15)

Orange powder, mp 258–260 °C, 80% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.41 (s, 3H, CH₃), 7.71–7.75 (m, 2H, 1H Ar + 1H C₅H-thiazole), 8.02–8.05 (d, *J* = 8.8 Hz, 2H, Ar), 8.16–8.18 (m, 1H, Ar), 8.28–8.30 (d, *J* = 8.8 Hz, 2H, Ar), 8.32–8.35 (m, 1H, Ar), 8.74 (s, 1H, Ar), 11.73 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₇H₁₃N₅O₄S: C, 53.26; H, 3.42; N, 18.27. Found: C, 53.01; H, 3.18; N, 18.43.

4.1.16. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(pyridin-2-ylmethylene)hydrazine (16)

Characterisation data were in agreement with those reported in the literature²⁹.

4.1.17. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine (17)

Characterisation data were in agreement with those reported in the literature³⁰.

4.1.18. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine (18)

Characterisation data were in agreement with those reported in the literature³¹.

4.1.19. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)ethylidene)hydrazine (19)

Characterisation data were in agreement with those reported in the literature³⁰.

4.1.20. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)ethylidene)hydrazine (20)

Characterisation data were in agreement with those reported in the literature³⁰.

4.1.21. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)ethylidene)hydrazine (21)

Characterisation data were in agreement with those reported in the literature³⁰.

4.1.22. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyrazin-2-yl)ethylidene)hydrazine (22)

Yellow powder, mp 243–245 °C, 85% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.41 (s, 1H, CH₃), 7.71–7.75 (m, 1H, Ar), 7.77 (s, 1H, C₅H-thiazole), 8.16–8.18 (m, 1H, Ar), 8.33–8.35 (m, 1H, Ar), 8.59–8.60 (m, 1H, Ar), 8.63–8.64 (m, 1H, Ar), 8.74–8.75 (m, 1H, Ar), 9.22–9.23 (m, 1H, Ar), 11.82 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₅H₁₂N₆O₂S: C, 52.93; H, 3.55; N, 24.69. Found: C, 53.20; H, 3.74; N, 24.84.

4.1.23. 1-((1H-Indol-3-yl)methylene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (23)

Yellow powder, mp 253–255 °C, 83% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.20–7.25 (m, 2H, Ar), 7.45–7.47 (m, 1H, Ar), 7.62 (s, 1H, C₅H-thiazole), 7.70–7.74 (m, 1H, Ar), 7.79–7.80 (m, 1H, Ar), 8.15–8.17 (m, 1H, Ar), 8.23–8.25 (m, 1H, Ar), 8.29–8.33 (m, 2H, Ar), 8.70 (s, 1H, =CH), 11.55 (bs, 1H, NH-indole, D₂O exch.), 11.98 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-*d*₆): δ 106.0 (Ar-C5, thiazole), 112.0 (Ar, indole), 112.4 (Ar, indole), 120.4 (Ar), 121.0 (Ar, indole), 122.1 (Ar), 122.5 (Ar, indole), 123.1 (Ar, indole), 124.5 (Ar, indole), 130.3 (Ar, indole), 130.7 (Ar), 132.1 (Ar), 136.6 (Ar), 137.6 (Ar, indole), 140.6 (C=N), 148.0 (Ar-NO₂), 148.7 (Ar-C4, thiazole), 168.7 (C=N, thiazole). Anal. Calcd for C₁₈H₁₃N₅O₂S: C, 59.49; H, 3.61; N, 19.27. Found: C, 59.65; H, 3.39; N, 19.49.

4.1.24. 1-(1-(1H-Indol-3-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (24)

Green powder, mp 209–211 °C, 87% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.36 (s, 3H, CH₃), 7.25–7.28 (m, 2H, 1H C₅H-thiazole + 1H Ar), 7.43–7.47 (m, 1H, Ar), 7.63–7.90 (m, 3H, Ar), 8.12–8.21 (m, 1H, Ar), 8.31–8.50 (m, 2H, Ar), 8.78 (s, 1H, Ar), 11.08 (bs, 1H, NH-indole, D₂O exch.), 11.48 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₉H₁₅N₅O₂S: C, 60.46; H, 4.01; N, 18.56. Found: C, 60.70; H, 3.83; N, 18.37.

4.1.25. 1-(Benzo[d][1,3]dioxol-5-ylmethylene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (25)

Yellow powder, mp 255–256 °C, 84% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 6.08 (s, 2H, OCH₂O), 6.96–6.98 (m, 1H, Ar), 7.11–7.13 (m, 1H, Ar), 7.23 (s, 1H, Ar), 7.63 (s, 1H, C₅H-thiazole), 7.68–7.72 (m, 1H, Ar), 7.96 (s, 1H, Ar), 8.13–8.15 (m, 1H, Ar), 8.28–8.30 (m, 1H, Ar), 8.66 (s, 1H, =CH), 12.17 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-*d*₆): δ 101.9 (OCH₂O, benzodioxole), 105.1 (Ar, benzodioxole), 106.7 (Ar-C5, thiazole), 109.0 (Ar, benzodioxole), 120.4 (Ar), 122.4 (Ar), 122.7 (Ar, benzodioxole), 129.2 (Ar, benzodioxole), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 142.0 (C=N), 148.4 (Ar-NO₂), 148.6 (Ar, benzodioxole), 148.7 (Ar-C4, thiazole), 149.0 (Ar,

benzodioxole), 169.1 (C=N, thiazole). Anal. Calcd for C₁₇H₁₂N₄O₄S: C, 55.43; H, 3.28; N, 15.21. Found: C, 55.22; H, 3.04; N, 15.39.

4.1.26. 1-(1-(Benzofuran-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (26)

Pink powder, mp 228–230 °C, 81% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.37 (s, 3H, CH₃), 7.25–7.29 (m, 1H, Ar), 7.31 (s, 1H, C₅H-thiazole), 7.34–7.37 (m, 1H, Ar), 7.61–7.63 (m, 4H, Ar) 8.14–8.16 (m, 1H, Ar), 8.32–8.34 (m, 1H, Ar), 8.73 (s, 1H, Ar), 11.61 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-*d*₆): δ 14.3 (CH₃), 106.6 (Ar-C5, thiazole), 107.7 (Ar, benzofuran), 111.7 (Ar, benzofuran), 120.5 (Ar), 122.0 (Ar, benzofuran), 122.5 (Ar), 123.8 (Ar, benzofuran), 125.9 (Ar, benzofuran), 128.6 (Ar, benzofuran), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 139.1 (C=N), 148.6 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 154.0 (Ar, benzofuran), 155.0 (Ar, benzofuran), 169.9 (C=N, thiazole). Anal. Calcd for C₁₉H₁₄N₄O₃S: C, 60.31; H, 3.73; N, 14.81. Found: C, 60.07; H, 3.97; N, 15.00.

4.1.27. 1-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (27)

Orange powder, mp 242–244 °C, 70% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.28 (s, 3H, CH₃), 4.28 (s, 4H, benzodioxine), 6.89–6.91 (m, 1H, Ar), 7.27–7.29 (m, 2H, Ar), 7.66 (s, 1H, C₅H-thiazole), 7.70–7.74 (t, 1H, Ar), 8.15–8.17 (m, 1H, Ar), 8.31–8.33 (m, 1H, Ar), 8.73 (s, 1H, Ar), 11.28 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-*d*₆): δ 14.5 (CH₃), 64.5 (CH₂), 64.7 (CH₂), 107.2 (Ar-C5, thiazole), 114.9 (Ar, benzodioxine), 117.4 (Ar, benzodioxine), 119.5 (Ar, benzodioxine), 120.4 (Ar), 122.4 (Ar), 130.7 (Ar), 131.6 (Ar, benzodioxine), 132.0 (Ar), 136.7 (Ar), 143.6 (C=N), 144.7 (Ar, benzodioxine), 147.1 (Ar, benzodioxine), 148.5 (Ar-NO₂), 148.7 (Ar-C4, thiazole), 170.7 (C=N, thiazole). Anal. Calcd for C₁₉H₁₆N₄O₄S: C, 57.57; H, 4.07; N, 14.13. Found: C, 57.80; H, 3.84; N, 58.02.

4.1.28. 1-(Naphthalen-1-ylmethylene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (28)

Orange powder, mp 212–214 °C, 72% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.59–7.63 (m, 2H, Ar), 7.67–7.75 (m, 3H, 2H Ar + 1H C₅H-thiazole), 7.87–7.89 (d, *J* = 8.0 Hz, 1H, Ar), 7.99–8.03 (t, 2H, Ar), 8.16–8.18 (m, 1H, Ar), 8.33–8.35 (d, *J* = 8.0 Hz, 1H, Ar), 8.70–8.71 (m, 2H, 1H Ar + 1H =CH), 8.77–8.79 (d, *J* = 8.0 Hz, 1H, Ar), 12.52 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₂₀H₁₄N₄O₂S: C, 64.16; H, 3.77; N, 14.96. Found: C, 63.92; H, 3.90; N, 15.12.

4.1.29. 1-(1-(Naphthalen-1-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (29)

White powder, mp 226–228 °C, 74% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.33 (s, 3H, CH₃), 7.54–7.59 (m, 4H, 3H Ar + 1H C₅H-thiazole), 7.91–8.00 (m, 4H, Ar), 8.26–8.41 (m, 2H, Ar), 8.56–8.58 (m, 1H, Ar), 8.71–8.75 (m, 1H, Ar), 12.14 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₂₁H₁₆N₄O₂S: C, 64.93; H, 4.15; N, 14.42. Found: C, 65.10; H, 3.89; N, 14.21.

4.1.30. 1-(1-(Naphthalen-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (30)

Yellow powder, mp 152–154 °C, 77% yield; ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.36 (s, 3H, CH₃), 7.53–7.55 (m, 2H, Ar), 7.70–7.72 (m, 2H, 1H Ar + 1H C₅H-thiazole), 7.90–7.94 (m, 2H, Ar), 7.96–7.98 (m, 1H, Ar), 8.03–8.05 (m, 1H, Ar), 8.07–8.09 (m, 1H, Ar), 8.22–8.24

(m, 1H, Ar), 8.41–8.43 (m, 1H, Ar), 8.74–8.75 (m, 1H, Ar), 11.54 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₂₁H₁₆N₄O₂S: C, 64.93; H, 4.15; N, 14.42. Found: C, 64.74; H, 4.36; N, 14.65.

4.1.31. 1-(1-(4-Acetylphenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (31)

Yellow powder, mp 205–207 °C, 79% yield; ¹H NMR (400 MHz, CDCl₃): δ 2.44 (s, 3H, CH₃), 2.66 (s, 3H, CH₃), 7.10 (s, 1H, C₅H-thiazole), 7.64–7.66 (t, 1H, Ar), 7.90–7.92 (d, *J* = 8.4 Hz, 2H, Ar), 8.02–8.04 (d, *J* = 8.0 Hz, 2H, Ar), 8.15–8.17 (d, *J* = 6.8 Hz, 1H, Ar), 8.21–8.23 (d, *J* = 6.8 Hz, 1H, Ar), 8.65 (s, 1H, Ar), 10.15 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 14.3 (CH₃), 27.2 (CH₃), 107.7 (Ar-C5, thiazole), 120.5 (Ar), 122.5 (Ar), 126.2 (2 × Ar), 128.8 (2 × Ar), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 136.9 (Ar), 142.4 (C=N), 146.0 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 170.3 (C=N, thiazole), 197.9 (C=O). Anal. Calcd for C₁₉H₁₆N₄O₃S: C, 59.99; H, 4.24; N, 14.73. Found: C, 60.15; H, 4.03; N, 15.00.

4.1.32. 1-(Diphenylmethylene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (32)

Yellow powder, mp 166–168 °C, 83% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.05 (s, 1H, C₅H-thiazole), 7.39–7.43 (m, 5H, Ar), 7.62–7.67 (m, 6H, Ar), 8.14–8.25 (m, 2H, Ar), 8.58 (s, 1H, Ar), 10.15 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 105.7 (Ar-C5, thiazole), 120.7 (Ar), 122.6 (Ar), 127.4 (2 × Ar), 128.4 (2 × Ar), 128.6 (2 × Ar), 129.7 (Ar), 129.8 (Ar), 130.0 (2 × Ar), 130.2 (Ar), 131.5 (Ar), 131.6 (Ar), 135.3 (C=N), 136.6 (Ar), 147.4 (Ar-NO₂), 148.7 (Ar-C4, thiazole), 168.8 (C=N, thiazole). Anal. Calcd for C₂₂H₁₆N₄O₂S: C, 65.98; H, 4.03; N, 13.99. Found: C, 66.14; H, 4.21; N, 14.17.

4.1.33. 1-(1-(Coumarin-3-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (33)

Red powder, mp 183–185 °C, 75% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.26 (s, 3H, CH₃), 6.60 (s, 1H, C₅H-thiazole), 6.86–6.87 (m, 1H, Ar), 7.66–7.79 (m, 5H, Ar), 8.15–8.17 (m, 1H, Ar), 8.31–8.33 (m, 1H, Ar), 8.72 (s, 1H, Ar), 11.35 (bs, 1H, NH, D₂O exch.). ¹³C NMR (101 MHz, DMSO-d₆): δ 14.2 (CH₃), 107.3 (Ar-C5, thiazole), 110.6 (Ar, coumarin), 112.3 (Ar, coumarin), 120.4 (Ar), 122.4 (Ar), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 139.7 (Ar, coumarin), 144.6 (C=N), 148.6 (Ar-NO₂), 148.8 (Ar-C4, thiazole), 152.2 (C=O, coumarin), 170.2 (C=N, thiazole). Anal. Calcd for C₂₀H₁₄N₄O₄S: C, 59.11; H, 3.47; N, 13.79. Found: C, 58.94; H, 3.24; N, 13.98.

4.1.34. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(phenanthren-3-yl)ethylidene)hydrazine (34)

Pink powder, mp 255–257 °C, 72% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 1.24 (s, 3H, CH₃), 7.25 (s, 2H, 1H Ar + 1H C₅H-thiazole), 7.37–7.48 (m, 5H, Ar), 7.61–7.69 (m, 5H, Ar), 8.01–8.03 (d, *J* = 8.4 Hz, 2H, Ar), 11.40 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₂₅H₁₈N₄O₂S: C, 68.48; H, 4.14; N, 12.78. Found: C, 68.30; H, 3.97; N, 12.54.

4.1.35. 1-(1-(Ferrocen-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (35)

Orange powder, mp 156–158 °C, 80% yield; ¹H NMR (400 MHz, CDCl₃): δ 2.49 (s, 3H, CH₃), 4.24 (s, 4H, ferrocene), 4.34 (s, 1H, ferrocene), 4.50 (s, 2H, ferrocene), 4.72 (s, 2H, ferrocene), 6.99 (s, 1H, C₅H-thiazole), 7.79 (s, 1H, Ar), 8.22–8.32 (m, 2H, Ar), 8.58 (s, 1H,

Ar), 12.35 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₂₁H₁₈FeN₄O₂S: C, 56.51; H, 4.07; N, 12.55. Found: C, 56.73; H, 4.29; N, 12.80.

4.1.36. 1,4-bis(1-(2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazono)ethyl)-benzene (36)

Orange powder, mp 283–285 °C, 81% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 2.37 (s, 6H, 2 × CH₃), 7.71–7.75 (m, 3H, 1H Ar + 2H 2 × C₅H-thiazole), 7.86 (bs, 3H, Ar), 7.87–7.88 (m, 1H, Ar), 7.89–7.90 (m, 1H, Ar), 8.16–8.18 (m, 2H, Ar), 8.33–8.35 (m, 2H, Ar), 8.75 (s, 2H, Ar), 11.45 (bs, 2H, 2 × NH, D₂O exch.). Anal. Calcd for C₂₈H₂₂N₈O₄S₂: C, 56.18; H, 3.70; N, 18.72. Found: C, 56.01; H, 3.96; N, 18.55.

4.1.37. 1-(4-(3-Aminophenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)ethylidene)hydrazine (37)

Red powder, mp 165–167 °C, 71% yield; ¹H NMR (400 MHz, DMSO-d₆): δ 5.15 (bs, 2H, NH₂, D₂O exch.), 6.50 (s, 1H, C₅H-thiazole), 6.99–7.12 (m, 5H, 4H Ar + 1H thiophene), 7.36 (s, 1H, thiophene), 7.58–7.59 (m, 1H, thiophene), 8.21 (s, 1H, CH=), 12.06 (bs, 1H, NH, D₂O exch.). Anal. Calcd for C₁₄H₁₂N₄S₂: C, 55.97; H, 4.03; N, 18.65. Found: C, 56.15; H, 3.84; N, 18.37.

4.2. MAO-A and MAO-B inhibition studies

4.2.1. Determination of IC₅₀ values

The procedure for the measurement of IC₅₀ values for the inhibition of MAO has been reported³². The enzyme reactions were prepared to a volume of 200 μM in potassium phosphate buffer at pH 7.4 (100 mM, made isotonic with KCl) and contained kynuramine (50 μM) and the test inhibitors (0.003–100 μM). Stock solutions of the test inhibitors were prepared in DMSO and added to the reactions to yield 4% DMSO. The enzyme reactions were initiated with the addition of recombinant hMAO-A (0.0075 mg protein/mL) or hMAO-B (0.015 mg protein/mL) and incubated for 20 min at 37 °C. At endpoint, the reactions were terminated with 80 μL sodium hydroxide (2N) and the fluorescence of 4-hydroxyquinoline, the oxidation product of kynuramine, was measured (λ_{ex} = 310; λ_{em} = 400 nm)³³. 4-Hydroxyquinoline was quantified with a calibration curve (0.047–1.56 μM) and the rate of 4-hydroxyquinoline formation was fitted to the one site competition model of the Prism 5 software package (GraphPad). From the resulting sigmoidal plots, the IC₅₀ values were estimated. All enzyme reactions were carried out in triplicate and IC₅₀ values are given as the mean ± standard deviation (SD).

4.2.2. Investigating reversibility of inhibition by dialysis

The procedure for the measurement of IC₅₀ values for the inhibition of MAO has been reported³². hMAO-B (0.03 mg/mL) and the test compounds (at 4 × IC₅₀) were incubated for 15 min at 37 °C to a final volume of 0.8 ml in dialysis buffer, potassium phosphate buffer (100 mM, pH 7.4) containing 5% sucrose. Stock solutions of the test compounds were prepared in DMSO and added to the incubations to yield 4% DMSO. The samples were dialyzed for 24 h at 4 °C in 80 ml of dialysis buffer using Slide-A-Lyzer[®] dialysis cassettes (Thermo Scientific) with a molecular weight cut-off of 10,000 and a sample volume capacity of 0.5–3 ml. The dialysis buffer was replaced at 3 and 7 h after the start of dialysis. Following dialysis, the dialysis samples were diluted twofold with the addition of kynuramine to yield a kynuramine concentration and inhibitor concentration of 50 μM and 2 × IC₅₀, respectively.

The reactions (500 μ L) were incubated for 20 min at 37 °C and terminated with NaOH (400 μ L, 2 N) and water (1000 μ L). The fluorescence of 4-hydroxyquinoline in these samples was measured as described for the IC₅₀ determination above. As controls, MAO-B was similarly pre-incubated and dialyzed in the absence of inhibitor (negative control) as well as in the presence of the irreversible inhibitor, (R)-(-)-deprenyl (positive control; IC₅₀ = 0.079 μ M)³⁴. Undialysed mixtures of MAO-B and the test inhibitors were maintained at 4 °C for 24 h and diluted and assayed as above. All reactions were carried out in triplicate and the residual enzyme catalytic rates are expressed as mean \pm SD.

4.2.3. Lineweaver–Burk plots

To construct Lineweaver–Burk plots, the enzyme reactions were carried out to a volume of 500 μ L and the concentration of MAO-B was 0.015 mg protein/mL. All enzyme reactions and activity measurements were carried out as described above for the dialysis experiments. The first plot was constructed in the absence of inhibitor, while the remaining five plots were constructed in the presence of the following concentrations: $\frac{1}{4} \times$ IC₅₀, $\frac{1}{2} \times$ IC₅₀, $\frac{3}{4} \times$ IC₅₀, $1 \times$ IC₅₀ and $1\frac{1}{4} \times$ IC₅₀. For each line, kynuramine was used at concentrations of 15–250 μ M. The K_i value was estimated from a plot of the slopes of the Lineweaver–Burk plots versus inhibitor concentration (x-axis intercept equals $-K_i$).

4.3. Antioxidant activity evaluation

4.3.1. Phosphomolybdenum assay (PhosphoMo)

The total antioxidant activity of the compounds was evaluated by phosphomolybdenum method according to Zengin et al.³⁵. The sample solution (0.3 ml) was combined with 3 ml of reagent solution (0.6 M sulphuric acid, 28 mM sodium phosphate, and 4 mM ammonium molybdate) and the absorbance was recorded at 695 nm after 90 min incubation at 95 °C. The EC₅₀, which is the effective concentration at which the absorbance was 0.5, was calculated for each compound and trolox, as a reference drug.

4.3.2. Radical scavenging activity (DPPH and ABTS)

The radical scavenging effect of the compounds using the the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical was estimated according to Zengin et al.³⁶. The sample solution (1 ml) was added to 4 ml of a 0.004% solution of DPPH in methanol. The sample absorbance was recorded at 517 nm after 30 min incubation at room temperature in the dark.

The scavenging activity of the compounds on the ABTS radical cation [ABTS, 2,2'-azino-bis(3-ethylbenzothiazoline)-6-sulphonic acid] was measured according to the method of Zengin et al.³⁷ with slight modification. Briefly, ABTS⁺ was produced directly by reacting a 7 mM ABTS solution with 2.45 mM potassium persulphate and allowing the mixture to incubate for 12–16 h in the dark at room temperature. Prior to initiating the assay, the ABTS solution was diluted with methanol to an absorbance of 0.700 \pm 0.02 at 734 nm. The sample solution (1 ml) was added to the ABTS⁺ solution (2 ml) and mixed, and the sample absorbance was recorded at 734 nm after 30 min incubation at room temperature. The corresponding IC₅₀ value, which is the effective concentration at which 50% of DPPH/ABTS radicals are scavenged, was calculated for each compound and trolox, as a reference drug.

4.3.3. Reducing power tests (CUPRAC and FRAP)

The cupric ion reducing activity (CUPRAC) was determined according to the method of Zengin et al.³⁸. The sample solution (0.5 ml) was added to a premixed reaction mixture containing CuCl₂ (1 ml, 10 mM), neocuproine (1 ml, 7.5 mM), and NH₄Ac buffer (1 ml, 1 M, pH 7.0). Similarly, a blank was prepared by adding the sample solution (0.5 ml) to a premixed reaction mixture (3 ml) without CuCl₂. The absorbances of the sample and blank were subsequently recorded at 450 nm after 30 min incubation at room temperature. The absorbance of the blank was subtracted from that of the sample.

The FRAP (ferric reducing antioxidant power) assay was carried out as described by Zengin et al.³⁸. The sample solution (0.1 ml) was added to the premixed FRAP reagent (2 ml) containing acetate buffer (0.3 M, pH 3.6), 2,4,6-tris(2-pyridyl)-s-triazine (10 mM) in 40 mM HCl, and ferric chloride (20 mM) in a ratio of 10/1/1 (v/v/v). The absorbance of the sample was subsequently recorded at 593 nm after 30 min incubation at room temperature. Both results were expressed as EC₅₀ values, using trolox as a reference drug.

4.3.4. Metal chelating activity on ferrous ions

Metal chelating activity on ferrous ions was evaluated by the method previously described³⁹. Briefly, the sample solution (2 ml) was added to FeCl₂ solution (0.05 ml, 2 mM). The reaction was initiated by the addition of 5 mM ferrozine (0.2 ml). Similarly, a blank was prepared by adding the sample solution (2 ml) to FeCl₂ solution (0.05 ml, 2 mM) and water (0.2 ml) without ferrozine. Then, the sample and blank absorbance were recorded at 562 nm after incubation for 10 min at room temperature. The absorbance of the blank was subtracted from that of the sample. EDTA was used as a positive control and this property was expressed as IC₅₀ value for each compound.

4.4. Molecular modelling


The Schrödinger suite 2018-1⁴⁰ was used to perform all molecular modelling studies with the OPLS⁴¹ as force field. Three-dimensional structures of the 4-(3-nitrophenyl)thiazol-2-ylhydrazones derivatives **3**, **4**, **13**, **37** were built by means the Maestro GUI and their oral absorption and blood–brain barrier permeation were theoretically predicted by the QikProp⁴² tool. Target protein structures were obtained from the Protein Data Bank (PDB)⁴³. In particular, the PDB crystallographic entries 6FW0⁴⁴, 2Z5X⁴⁵, 4MOE⁴⁶, and 1POI⁴⁷ were selected as theoretical models for hMAO-B, hMAO-A, hAChE, and hBuChE, respectively. Each target structure was submitted to preliminary manipulations by adding missing hydrogen atoms, deleting water molecules, removing co-crystallised ligands, and fixing FAD bonding orders. Molecular docking simulations were carried out with Glide⁴⁸ flexible ligand implementation using the extra precision (XP) search algorithm. For the protein binding sites, a grid box of about 64,000 Å³ centred on the FAD N5 atom in the MAOs and on catalytic Ser203 in the ChEs was considered. The default docking scoring function was applied for ranking ligand binding modes. Finally, ZINC PAINS Pattern Identifier⁴⁹ was used to evaluate if our derivatives could be considered as potential pan assays interfering or aggregator compounds.

5. Results and discussion

5.1. In vitro MAO inhibition study

The synthesised compounds reported here share a similar structure, with the principal differences among compounds **1–37** occurring at the **X** and **Y** substituents as shown in Scheme 1.

Table 1. Inhibitory activity (IC_{50}) and selectivity index (SI) of compounds 1–35 towards hMAO-A and hMAO-B.

		IC_{50} (μM) ^a		SI ^b
Compound	Hydrazone substituent	hMAO-A	hMAO-B	
1		8.98 ± 0.621	0.095 ± 0.0043	95
2		65.0 ± 6.32	21.0 ± 2.78	3.1
3		57.2 ± 13.4	0.0068 ± 0.00046	8412
4		1.66 ± 0.133	0.0018 ± 0.00012	922
5		6.47 ± 1.25	0.0025 ± 0.00015	2588
6		94.3 ± 1.60	0.048 ± 0.0051	1965
7		23.4 ± 2.68	0.027 ± 0.0057	867
8		39.2 ± 0.121	0.015 ± 0.00057	2613
9		12.8 ± 0.421	9.11 ± 1.60	1.4
10		87.9 ± 8.59	4.63 ± 0.901	19
11		4.73 ± 0.427	0.0071 ± 0.0011	666
12		2.83 ± 0.985	0.078 ± 0.012	36
13		15.3 ± 1.11	0.0044 ± 0.00020	3477
14		51.4 ± 5.97	0.063 ± 0.018	816
15		241 ± 26.8	145 ± 50.7	1.7
16		50.7 ± 2.65	0.141 ± 0.036	360
17		9.78 ± 0.326	0.212 ± 0.022	46
18		91.9 ± 8.80	0.081 ± 0.00043	1135
19		49.4 ± 2.40	0.103 ± 0.013	480
20		156 ± 16.3	0.050 ± 0.010	3120

(continued)

21		109 ± 8.55	0.014 ± 0.0026	7786
22		188 ± 11.1	0.024 ± 0.0065	7833
23		96.4 ± 6.88	0.336 ± 0.056	287
24		28.1 ± 3.32	4.52 ± 0.915	6.2
25		371 ± 42.8	112 ± 9.37	3.3
26		49.7 ± 2.34	13.7 ± 2.15	3.6
27		48.7 ± 1.38	9.55 ± 1.46	5.1
28		23.6 ± 0.082	0.045 ± 0.0064	524
29		123 ± 12.6	0.039 ± 0.0073	3154
30		286 ± 13.8	2.44 ± 0.634	117
31		227 ± 14.8	42.1 ± 2.98	5.4
32		236 ± 31.9	7.05 ± 3.76	33
33		4.82 ± 0.399	0.013 ± 0.0039	371
34		101 ± 8.80	80.5 ± 7.80	1.3
35		36.3 ± 2.19	0.103 ± 0.0090	352



^aValues are the mean ± SD of triplicate determinations.

^bSelectivity index for the MAO-B isoform, given as the ratio: (IC₅₀ hMAO-A)/(IC₅₀ hMAO-B).

These substitutions play a fundamental role and affect the activity and selectivity index (SI) of inhibition of the two hMAO isoforms. SI <1 indicates selectivity for MAO-A, whereas SI >1 indicates selectivity for the MAO-B isoform. All the tested compounds were found to inhibit the hMAO enzymes with selectivity for the hMAO-B isoform (Tables 1 and 2). The presence of aromatic/heterocyclic systems as Y moiety was effective in order to obtain derivatives that selectively inhibit hMAO-B in the nanomolar range. Among these compounds, the most active towards this isoform were the derivatives **4** (IC₅₀ hMAO-B = 0.0018 μM) and **5** (IC₅₀ hMAO-B = 0.0025 μM), both containing methyl as X group and respectively, thiophen-2-yl and thiophen-3-yl as Y substituent. Comparing the inhibitory activities of compound **4** and compound **3**, which contains H as X group, it can be noted that there was only a modest decrease in MAO-B inhibition activity for **3**, while a reduction in inhibition activity was more noticeable for hMAO-A

(IC₅₀ hMAO-A = 57.2 μM). This increased the SI by approximately 10-fold (from 922 for compound **4** to 8412 for compound **3**). A similar result was obtained for compound **6** where substitution on thiophenyl ring led to a reduction in inhibition activity towards hMAO-A compared to derivative **4**. Even though hMAO-B inhibition was also slightly reduced, the SI increased significantly (compare **6** vs. **4**). Among derivatives possessing furan as Y substituent (**1** and **2**), only compound **1** exhibited inhibition activity in the nanomolar range for hMAO-B (IC₅₀ hMAO-B = 0.095 μM). The lower activity of **2** suggests that isosteric replacement of the oxygen atom for a sulphur is unfavourable for MAO-B inhibition (compare **2** vs. **4**). Within the set of compounds containing the phenyl ring as Y moiety, we observed the best inhibitory activity for derivative **11** (IC₅₀ hMAO-B = 0.0071 μM), which contains methyl as X substituent. The absence of the methyl group (X = H, compound **7**) or its elongation to X = ethyl (compound **12**) were detrimental

Table 2. Inhibitory activity (IC₅₀) and selectivity index (SI) of compounds **36** and **37** towards hMAO-A and hMAO-B.

Compound	Structure	IC ₅₀ (μM) ^a		SI ^b
		hMAO-A	hMAO-B	
36		73.9 ± 3.32	17.6 ± 2.46	4.2
37		46.9 ± 4.12	2.67 ± 0.362	18

^aValues are the mean ± SD of triplicate determinations.

^bSelectivity index for the MAO-B isoform, given as the ratio: (IC₅₀ hMAO-A)/(IC₅₀ hMAO-B).

for MAO-B inhibition activity. Nitro-substitution on the phenyl ring, as with compounds **8–10** and **13–15**, was advantageous when done in the *ortho*-position (compound **13**, IC₅₀ hMAO-B = 0.0044 μM), a modification that also improved the selectivity compared with the unsubstituted derivative **11** (SI₁₁ = 666, SI₁₃ = 3477, respectively). On the other hand, substitution with an acetyl moiety in the *para*-position of phenyl ring reduced activity and selectivity as observed for compound **31** (IC₅₀ hMAO-B = 42.1 μM, SI₃₁ = 5.4). Compounds substituted with pyridine as **Y** moiety (**16–21**) possess nanomolar activity towards hMAO-B (0.014 μM < IC₅₀ hMAO-B < 0.212 μM), while poor potencies were recorded for hMAO-A inhibition, with IC₅₀ in the micromolar range (9.78 μM < IC₅₀ hMAO-A < 156 μM). Most of the compounds possessing a hetero-bicyclic system as **Y** moiety (compounds **23–27**) showed the loss of activity and selectivity, except for compound **33** that contains a coumarin moiety. Coumarin derivatives are well known to inhibit the hMAO enzymes as previously reported⁵⁰. Naphthyl as **Y** group was effective only when substituted in the α -position (compare **28** and **29** vs. **30**), while the presence of very bulky groups such as phenanthrene (compound **34**) reduced activity towards both isoforms (IC₅₀ hMAO-A = 101 μM, IC₅₀ hMAO-B = 80.5 μM). Finally, we evaluated the effect of dimerisation with compound **36** and the reduction of nitro group to obtain amine functionality with compound **37**. The IC₅₀ values showed that the dimerisation negatively affected inhibition activity, and this is likely related to the steric hindrance in the MAO active site. Compound **37**, on the other hand, showed loss of MAO-B inhibitory activity, which highlights the importance of the nitro group on the meta position for this scaffold (compare **37** vs. **3**). Conversely, the MAO-A inhibitory activity was not affected by nitro reduction.

Reversibility of MAO inhibition is an important factor to consider when evaluating the inhibition properties of potential inhibitors. Irreversible MAO inhibitors, particularly of the MAO-A isoform, are associated with dangerous adverse effects such as the cheese reaction, which occurs when irreversible MAO-A inhibitors are taken with tyramine-rich food⁵¹. To demonstrate that the 4-(3-nitrophenyl)thiazol-2-ylhydrazones derivatives studied here are reversible MAO inhibitors, compounds **4** and **37** were selected as test compounds. The reversibility of MAO-B inhibition was evaluated by incubating MAO-B in the presence of the test compounds (at a concentration of 4 × IC₅₀) for 15 min, and subsequently dialyzing the samples for 24 h. The samples were diluted twofold and the residual MAO-B activity was measured. For reversible inhibition, dialysis is expected to reverse inhibition by the test inhibitors and restore enzyme activity to the level of the negative control. The negative control consisted of similar

incubation and dialysis in the absence of inhibitor and represented 100% enzyme activity, while as positive control, these studies were carried out in the presence of the irreversible MAO-B inhibitor, (*R*)-(-)-deprenyl. A final experiment consisted of incubations containing MAO-B and tested inhibitors which were not dialyzed, but maintained for 24 h.

The results are given in Figures 1 and 2, and show that dialysis restored MAO-B activity for both **4** and **37**, with the residual activity at 61 and 97%, respectively. Compound **37** was thus a fully reversible MAO-B inhibitor, while **4** was partially reversible, which was likely due to tight-binding of this high potency inhibitor to the MAO-B active site. For (*R*)-(-)-deprenyl, dialysis did not restore enzyme activity with the residual MAO-B activity at 3% of the negative control value. In undialysed mixtures of **4** and **37**, inhibition persisted with the residual activity at 33 and 20%, respectively.

To provide further support for the reversibility of MAO-B inhibition by compounds **4** and **37**, a set of Lineweaver–Burk plots was constructed for each inhibitor at the following inhibitor concentrations: 1/4 × IC₅₀, 1/2 × IC₅₀, 3/4 × IC₅₀, 1 × IC₅₀, and 1 1/4 × IC₅₀. The substrate, kynuramine, was used at 15–250 μM for each line. The results are given in Figures 3 and 4, and show that the Lineweaver–Burk plots for both inhibitors are indicative of competitive, and therefore reversible inhibition. The lines of the plots intersect on the y-axis and a replot of the slopes versus inhibitor concentration yields a linear line, from which the enzyme-inhibitor dissociation constant (K_i) was estimated (K_i = -x-axis intercept). For compounds **4** and **37**, K_i values of 0.0026 and 1.84 μM are estimated.

5.2. In vitro antioxidant assays

It is a well-known that MAO-mediated oxidative metabolism of monoamines leads to the production of hydrogen peroxide as a by-product. Subsequently, this chemical species may be converted to free radicals through the Fenton reaction and thus contributes to the oxidative stress. Uncontrolled increases in the concentrations of these radicals initiates oxidative damage to several cellular components. Thus, the prevention of ROS generation along with MAO inhibition is an important strategy to prevent or limit neurotoxicity in NDDs. The capability of the most promising MAO inhibitors of this study to act as antioxidant agents has been evaluated *in vitro* by five experimental approaches, using trolox as the reference compound. As it can be seen from the results in Table 3, the tested compounds showed antioxidant activity that is only slightly lower than trolox, whereas in the reducing power assay (important for the inhibition of the Fenton reaction between metal ions and the by-products of MAO-mediated reaction) and total antioxidant capacity in the phosphomolybdenum (PhosphoMo) assay, the test and reference




Figure 1. Reversibility of the inhibition of hMAO-B by **4**. hMAO-B and **4** (at $4 \times IC_{50}$) were preincubated for 15 min, dialyzed for 24 h and the residual enzyme activity was measured (**4**, dialyzed). hMAO-B was similarly preincubated in the absence (No Inh, dialyzed) and presence of the irreversible inhibitor, (*R*)-(-)-deprenyl (depr, dialyzed), and dialyzed. For comparison, the residual hMAO activity of undialysed mixtures of hMAO-B with **4** is also shown (**4**, not dialyzed).




Figure 2. Reversibility of the inhibition of hMAO-B by **37**. hMAO-B and **37** (at $4 \times IC_{50}$) were preincubated for 15 min, dialyzed for 24 h and the residual enzyme activity was measured (**37**, dialyzed). hMAO-B was similarly preincubated in the absence (No Inh, dialyzed) and presence of the irreversible inhibitor, (*R*)-(-)-deprenyl (depr, dialyzed), and dialyzed. For comparison, the residual hMAO activity of undialysed mixtures of hMAO-B with **37** is also shown (**37**, not dialyzed).

compounds displayed almost comparable potencies. Chelating activity of ferrous ions, however, was almost absent for this scaffold. These ancillary biological activities could be useful for the treatment of multifactorial neurodegenerative diseases where oxidative stress enhances cognitive impairment and inflammatory processes.

The proposed mechanism for the antioxidant activity of this scaffold of compounds is depicted in [Scheme 2](#) using DPPH/ABTS. First the N–H group can readily donate a hydrogen radical to the DPPH/ABTS radical and generate a new radical species which is stabilised by resonance through the thiazole ring and the =C–N–N=C moiety. The new radical can be further stabilised by resonance through imine and thiazole structures. Since, the antioxidant activities using the ABTS and DPPH assay are comparable, it may be assumed that imine and thiazole moieties can participate in single electron transfer and lead to discrete antioxidant activity. Moreover, other resonance structures can be present⁵².

5.3. Molecular modelling

Target recognition of the most interesting compounds **3**, **4**, **13**, and **37**, as suggested by the experimental data, was investigated




Figure 3. Lineweaver–Burk plots of hMAO-B activities in the absence (filled squares) and presence of various concentrations of compound **4** ($IC_{50} = 0.0018 \mu\text{M}$). For these studies the concentrations of compound **4** employed were $1/4 \times IC_{50}$, $1/2 \times IC_{50}$, $3/4 \times IC_{50}$, $1 \times IC_{50}$ and $1 1/4 \times IC_{50}$. The inset is a graph of the slopes of the Lineweaver–Burk plots versus inhibitor concentration ($K_i = 0.0026 \mu\text{M}$).





Figure 4. Lineweaver–Burk plots of hMAO-B activities in the absence (filled squares) and presence of various concentrations of compound **37** ($IC_{50} = 2.67 \mu\text{M}$). For these studies the concentrations of compound **37** employed were: $1/4 \times IC_{50}$, $1/2 \times IC_{50}$, $3/4 \times IC_{50}$, $1 \times IC_{50}$ and $1 1/4 \times IC_{50}$. The inset is a graph of the slopes of the Lineweaver–Burk plots versus inhibitor concentration ($K_i = 1.84 \mu\text{M}$).

by molecular modelling simulations. In agreement with experimental data, docking results proposed, in general, preferred hMAO-B recognition compared to the A isoform. Indeed, all evaluated compounds presented better theoretical affinity for hMAO-B and thus more productive interactions with this isoform ([Figure 5](#)). For compound **13** no poses in hMAO-A active site were obtained ([Figure 6](#)).

The top poses obtained for **3**, **4**, and **37** showed similar orientations in the MAO-B active site, with the phenyl ring substituted at the meta position by nitro or amino group directed towards the FAD cofactor. A similar orientation for **13** appeared in a lower ranked pose only, since the best-scored pose showed interactions between the nitro group and the side chains of Thr201 and Glu84

Table 3. Antioxidant and chelating activities of the most promising derivatives compared to the reference drugs, EDTA and trolox.

Samples	Chelating activity IC ₅₀ (mM)	Antioxidant assays (mM)				
		PhosphoMo (EC ₅₀)	FRAP (EC ₅₀)	CUPRAC (EC ₅₀)	DPPH (IC ₅₀)	ABTS (IC ₅₀)
3	>5	1.84 ± 0.18	0.41 ± 0.02	0.59 ± 0.01	1.19 ± 0.01	1.05 ± 0.01
4	>5	1.68 ± 0.09	0.53 ± 0.02	0.52 ± 0.02	1.17 ± 0.01	1.04 ± 0.01
5	>5	1.16 ± 0.03	0.52 ± 0.02	0.48 ± 0.03	1.21 ± 0.01	1.05 ± 0.02
6	>5	1.25 ± 0.05	0.62 ± 0.07	0.49 ± 0.01	1.18 ± 0.01	1.08 ± 0.01
7	>5	1.29 ± 0.16	0.66 ± 0.04	0.66 ± 0.01	1.38 ± 0.01	1.04 ± 0.01
8	>5	1.70 ± 0.05	0.47 ± 0.04	0.44 ± 0.02	1.47 ± 0.01	1.04 ± 0.01
11	>5	1.46 ± 0.08	0.59 ± 0.01	0.55 ± 0.02	1.28 ± 0.01	1.04 ± 0.01
13	>5	3.10 ± 0.36	0.45 ± 0.04	0.40 ± 0.01	1.59 ± 0.01	1.04 ± 0.01
16	>5	1.13 ± 0.01	0.51 ± 0.02	0.53 ± 0.02	1.32 ± 0.01	1.06 ± 0.02
18	>5	4.70 ± 0.97	0.35 ± 0.01	0.58 ± 0.01	1.37 ± 0.01	1.04 ± 0.01
19	>5	2.64 ± 0.34	0.38 ± 0.02	0.51 ± 0.01	1.36 ± 0.01	1.04 ± 0.01
20	>5	1.77 ± 0.07	0.32 ± 0.02	0.42 ± 0.02	1.29 ± 0.01	1.04 ± 0.01
21	>5	4.48 ± 0.18	0.27 ± 0.01	0.46 ± 0.02	1.34 ± 0.02	1.04 ± 0.01
22	3.86 ± 0.29	1.28 ± 0.03	0.48 ± 0.04	0.91 ± 0.02	1.34 ± 0.01	1.04 ± 0.01
28	>5	4.93 ± 0.83	0.41 ± 0.01	0.51 ± 0.03	1.30 ± 0.01	1.05 ± 0.01
29	>5	9.39 ± 0.31	0.53 ± 0.02	0.46 ± 0.01	1.42 ± 0.01	1.04 ± 0.01
Trolox	-	1.13 ± 0.05	0.16 ± 0.01	0.24 ± 0.02	0.40 ± 0.01	0.66 ± 0.02
EDTA	0.02 ± 0.001	-	-	-	-	-

**Scheme 2.** The proposed mechanism for the antioxidant ability of compounds 1-37.

located at the entry of the active site. The reduction of the nitro group did not affect the docking outcomes to a significant degree, both in term of binding geometries and affinity energy values. In fact, the most energetically favourable orientations of **3** and **37** were superimposable and both were involved in stacking interactions with Tyr326 and Trp119 by means of the thiazole ring. The binding mode of **3** was further stabilised by a hydrogen bond between the hydrazone nitrogen atom and the Tyr326 side chain resulting in a moderately better theoretical affinity. The substitution of the hydrazone hydrogen atom by a methyl group in compound **4** led to a slightly different pose, characterised by the loss of the interactions produced by the thiazolyhydrazone core. In the hMAO-A binding site, **3** and **4** were oriented with the nitro group toward the cofactor, but binding occurred towards to the gorge entry. Such poses were strongly penalised with respect to the corresponding poses in the hMAO-B active site. This observation may be due to the replacement of Tyr326 in hMAO-B by Ile335 in hMAO-A. Furthermore, unfavourable steric clashes with

Val210 and Ile335 were present. Conversely to hMAO-B, the reduction of the nitro group in **37** induced an opposite binding mode in which the thiazole substituent was directed towards the FAD. Steric hindrance between **37** and Tyr407 and Tyr444 was unfavourable for ligand-target recognition. Docking of our derivatives in both ChEs (Figures 7 and 8) did not suggest a remarkable selectivity for a particular isoform. In hAChE, **3**, **4** and **13** displayed very similar binding modes and interacted with Trp286, Tyr124, Tyr341, and Trp86. Such poses seemed to be determined by the *m*-nitrophenyl moiety which interacted with the external tryptophan residue (Trp286). In fact, for **37** the opposite orientation occurred due to the loss of this productive interaction although contacts with the tyrosine residues and with the internal tryptophan (Trp86) were maintained. In hBuChE, where Ala277 replaces the hAChE Trp286, the compounds better recognised the internal Trp82 (corresponding to Trp86 in hAChE).

Computed pharmacokinetic properties indicated that all the derivatives evaluated may possess good absorption after oral




Figure 5. Glide top poses of compounds (a) **3**, (b) **4**, (c) **13**, and (d) **37** in the hMAO-B active site. Ligands are depicted in orange carbon polytube, the FAD is shown in lilac coloured CPK and the most relevant residues are reported in lilac carbon polytube. Hydrogen bonds, cation- π and π - π interactions are displayed in yellow, green and light blue respectively.




Figure 6. Glide top poses of compounds (a) **3**, (b) **4**, (c) **13**, and (d) **37** in the hMAO-A active site. Ligands are depicted in orange carbon polytube, the FAD is shown in lilac coloured CPK and the most relevant residues are reported in lilac carbon polytube. Hydrogen bonds, cation- π and π - π interactions are displayed in yellow, green and light blue respectively.

administration and the CNS availability of **3**, **4**, and **37** is comparable to known CNS drugs (Table 4)⁵³. None of the considered compounds were proposed as PAINS or aggregators by ZINC filter.

6. Conclusion

4-(3-Nitrophenyl)thiazol-2-ylhydrazones were demonstrated to be a very interesting scaffold which can be used to design high potency hMAO-B inhibitors, with IC_{50} values in the nanomolar range. The presence of specific moieties at the hydrazone linker

gave the most selective inhibition of this isozyme. These compounds are also characterised by a reversible and competitive mode of hMAO-B inhibition, as well as by discrete antioxidant properties. Moreover, the physical-chemical properties of the designed molecules were predicted *in silico* and were found to fit the requirements for CNS penetration. Additional interaction with the cholinesterases (AChE and BuChE) may be possible which suggests that 4-(3-nitrophenyl)thiazol-2-ylhydrazones are novel multi-target compounds and potential leads for the design of future therapies for NDDs.




Figure 7. Glide top poses of compounds (a) 3, (b) 4, (c) 13, and (d) 37 in the hAChE active site. Ligands are reported in orange carbon polytube and the most relevant residues are shown in green carbon polytube. Hydrogen bonds, cation- π and π - π interactions are displayed in yellow, green and light blue, respectively.




Figure 8. Glide top poses of compounds (a) 3, (b) 4, (c) 13, and (d) 37 in the hBuChE active site. Ligands are reported in orange carbon polytube and the most relevant residues are shown in green carbon polytube. Hydrogen bonds, cation- π and π - π interactions are displayed in yellow, green and light blue, respectively.

Table 4. Theoretical properties and docking scores of the most interesting compounds for binding to the hMAOs and hChEs.

Compound	%OA ^a	QlogBB ^b	Docking Score ^c			
			hMAO-A	hMAO-B	hAChE	hBuChE
3	95.14	-0.83	0.88	-9.86	-6.80	-6.80
4	100.00	-0.70	-6.10	-9.02	-7.03	-4.71
13	92.18	-1.17	0.81	-4.22	-5.39	-5.55
37	100.00	-0.47	-4.53	-9.45	-7.02	-7.04

^aPercentage of oral absorption.

^bBlood-brain barrier permeation as pLog(IN/OUT).

^cXP docking score in kcal/mol of the top poses.

Disclosure statement

The authors state no conflict of interest and they have received no payment in preparation of this manuscript.

The biological section of this study was funded in part by the National Research Foundation of South Africa [Grant specific unique reference numbers (UID) 85642, 96180]. The Grant holders acknowledge that opinions, findings and conclusions or recommendations expressed in any publication generated by the NRF supported research are that of the authors, and that the NRF accepts no liability whatsoever in this regard.

Funding

This work was supported by "Progetto di Ricerca Ateneo La Sapienza 2014 -C26A14AC5L" (Italy) and POR FESR LAZIO 2014/2020 – REGIONE LAZIO - Avviso pubblico LIFE 2020.

ORCID

Simone Carradori  <http://orcid.org/0000-0002-8698-9440>

Gokhan Zengin  <http://orcid.org/0000-0002-5165-6013>

References

- Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. *Cold Spring Harb Perspect Biol* 2017;9:a028035.
- Youdim MB, Kupersmidt L, Amit T, Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. *Parkinsonism Relat Disord* 2014;20:S132–S6.
- Cavalli A, Bolognesi ML, Minarini A. Multi-target-directed ligands to combat neurodegenerative diseases. *J Med Chem* 2008;51:347–72.
- Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. *Expert Rev Clin Pharmacol* 2011;4:293–8.
- Carradori S, Ortuso F, Petzer A. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. *Eur J Med Chem* 2018;143:1543–52.
- D'Ascenzio M, Chimenti P, Gidaro MC. (Thiazol-2-yl)hydrazone derivatives from acetylpyridines as dual inhibitors of MAO and AChE: synthesis, biological evaluation and molecular modeling studies. *J Enzyme Inhib Med Chem* 2015;30:908–19.
- Riederer P, Müller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. *Expert Opin Drug Metab Toxicol* 2017;13:233–40.
- Carradori S, Secci D, Petzer JP. MAO inhibitors and their wider applications: a patent review. *Expert Opin Ther Patents* 2018;28:211–26.
- De Monte C, D Ascenzio M, Guglielmi P, et al. Opening new scenarios for human MAO inhibitors. *Cent Nerv Syst Agents Med Chem* 2016;16:98–104.
- Carradori S, Petzer JP. Novel monoamine oxidase inhibitors: a patent review (2012 - 2014). *Expert Opin Ther Pat* 2015;25:91–110.
- Carradori S, Secci D, Bolasco A, et al. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. *Expert Opin Ther Patents* 2012;22:759–801.
- Bolasco A, Carradori S, Fioravanti R. Focusing on new monoamine oxidase inhibitors. *Expert Opin Ther Patents* 2010;20:909–39.
- Bolasco A, Fioravanti R, Carradori S. Recent development of monoamine oxidase inhibitors. *Expert Opin Ther Patents* 2005;15:1763–82.
- Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. *Gene* 2013;532:18–23.
- Szökö É, Tábi T, Riederer P, et al. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. *J Neural Transm* 2018;125:1735–49.
- Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson's disease. *Expert Opin Investig Drugs* 2008;17:1115–25.
- Schedin-Weiss S, Inoue M, Hromadkova L. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ -secretase and regulates neuronal amyloid β -peptide levels. *Alzheimer's Res Ther* 2017;9:57.
- Chimenti F, Maccioni E, Secci D, et al. Synthesis, stereochemical identification and selective inhibitory activity against hMAO-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. *J Med Chem* 2008;51:4874–80.
- Chimenti P, Petzer A, Carradori S, et al. Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors. *Eur J Med Chem* 2013;66:221–7.
- Carradori S, D'Ascenzio M, De Monte C, et al. Synthesis and selective human monoamine oxidase B inhibition of heterocyclic hybrids based on hydrazine and thiazole scaffolds. *Arch. Pharm. (Weinheim)* 2013;346:17–22.
- Secci D, Bolasco A, Carradori S, et al. Recent advances in the development of selective human MAO-B inhibitors: (Hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines. *Eur J Med Chem* 2012;58:405–17.
- Chimenti F, Secci D, Bolasco A, et al. Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines. *J Med Chem* 2010;53:6516–20.
- Chimenti F, Secci D, Bolasco A, et al. Investigations on the 2-thiazolylhydrazine scaffold: synthesis and molecular modeling of potent and selective human monoamine oxidase inhibitors. *Bioorg Med Chem* 2010;18:5715–23.
- Chimenti F, Secci D, Bolasco A, et al. Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. *Bioorg Med Chem* 2010;18:5063–70.
- Chimenti F, Secci D, Bolasco A, et al. Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones. *Med Chem Commun* 2010;1:61–72.
- D'Ascenzio M, Carradori S, Secci D, et al. Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenehydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors. *Bioorg Med Chem* 2014;22:2887–95.
- Antonini I, Claudi F, Franchetti P, et al. Elucidation of the structure of the antineoplastic agents, 2-formylpyridine and 1-formylisoquinoline thiosemicarbazones. *J Med Chem* 1977;20:447–9.
- Youssef AF, Farag HH, Omar NM, et al. Synthesis and antibacterial screening of 2-(arylidenehydrazino)-4-phenylthiazole derivatives. *Egypt J Pharm Sci* 1980;19:247–52.
- Cardoso MV, de Siqueira LR, da Silva E, et al. 2-Pyridyl thiazoles as novel anti-*Trypanosoma cruzi* agents: structural design, synthesis and pharmacological evaluation. *Eur J Med Chem* 2014;86:48–59.
- Ali F, Khan KM, Salar U, et al. Hydrazinyl arylthiazole based pyridine scaffolds: synthesis, structural characterization, in vitro α -glucosidase inhibitory activity, and in silico studies. *Eur J Med Chem* 2017;138:255–72.
- Galvez-Llompert M, del Carmen Recio Iglesias M, Gálvez J, García-Domenech R. Novel potential agents for ulcerative

- colitis by molecular topology: suppression of IL-6 production in Caco-2 and RAW 264.7 cell lines. *Mol Div* 2013;17:573–93.
32. Mostert S, Petzer A, Petzer JP. Indanones as high-potency reversible inhibitors of monoamine oxidase. *ChemMedChem* 2015;10:862–73.
 33. Novaroli L, Reist M, Favre E, et al. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. *Bioorg Med Chem* 2005;13:6212–17.
 34. Petzer A, Harvey BH, Wegener G, Petzer JP. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. *Toxicol Appl Pharmacol* 2012;258:403–9.
 35. Zengin G, Sarikurkcü C, Aktumsek A, et al. A comprehensive study on phytochemical characterization of *Haplophyllum myrtifolium* Boiss. endemic to Turkey and its inhibitory potential against key enzymes involved in Alzheimer, skin diseases and type II diabetes. *Ind Crop Prod* 2014;53:244–51.
 36. Zengin G, Sarikurkcü C, Gunes E, et al. Two *Ganoderma* species: profiling of phenolic compounds by HPLC-DAD, antioxidant, antimicrobial and inhibitory activities on key enzymes linked to diabetes mellitus, Alzheimer's disease and skin disorders. *Food Funct* 2015;6:2794–802.
 37. Aktumsek A, Zengin G, Guler GO, et al. Antioxidant potentials and anticholinesterase activities of methanolic and aqueous extracts of three endemic *Centaurea* L. species. *Food Chem. Toxicol* 2013;55:290–6.
 38. Zengin G, Ceylan R, Guler GO, et al. Enzyme inhibitory effect and antioxidant properties of *Astragalus lagurus* extracts. *Curr Enzyme Inhib* 2016;12:177–82.
 39. Locatelli M, Zengin G, Uysal A, et al. Multicomponent pattern and biological activities of seven *Asphodeline* taxa: Potential sources of natural-functional ingredients for bioactive formulations. *J Enzyme Inhib Med Chem* 2017;32:60–7.
 40. Schrödinger, LLC, New York, NY, 2018.
 41. Harder E, Damm W, Maple J, et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. *J Chem Theory Comput* 2016;12:281–96.
 42. Schrödinger. Qikprop. New York (NY): Schrödinger, LLC; 2018.
 43. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. *Nucleic Acids Res* 2000;28:235–42.
 44. Reis J, Manzella N, Cagide F, et al. Tight-binding inhibition of human monoamine oxidase B by chromone analogs: a kinetic, crystallographic, and biological analysis. *J Med Chem* 2018;61:4203–12.
 45. Son SY, Ma J, Kondou Y, et al. Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for substrates/inhibitors. *Proc Natl Acad Sci USA* 2008;105:5739–44.
 46. Cheung J, Gary EN, Shiomi K, Rosenberry TL. Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrein B show peripheral site flexibility. *ACS Med Chem Lett* 2013;4:1091–6.
 47. Nicolet Y, Lockridge O, Masson P, et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. *J Biol Chem* 2003;278:41141–7.
 48. Schrödinger. Glide. New York (NY): Schrödinger, LLC; 2018.
 49. Available from: <http://zinc15.docking.org/patterns/home> [accessed date 30 Oct 2018].
 50. Carradori S, Silvestri R. New frontiers in selective human MAO-B inhibitors. *J Med Chem* 2015;58:6717–32.
 51. Da Prada M, Zürcher G, Wüthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. *J Neural Transm Suppl* 1988;26:31–56.
 52. Maltarollo VG, de Resende MF, Kronenberger T, et al. In vitro and in silico studies of antioxidant activity of 2-thiazolylhydrazones derivatives. *J Mol Graph Model* 2019;86:106–12.
 53. Luco JM. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. *J Chem Inf Comput* 1999;39:396–404.